Clinical Trials · NCT05421338
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 6
- Start date
- Jul 2022
- Locations
- 1 site, Netherlands
- Primary endpoint
- Fraction of [14C]-radioactivity excreted in urine expressed as percentage of the administered dose over the time interval from 0 to the last quantifiable time point (fe_urine, 0-tz)